康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01681 康臣药业

未开盘 10-20 16:08:20

16.040

+0.360

+2.30%

最高16.180	最低15.730	成交量230.00万
今开15.730	昨收15.680	日振幅2.87%
总市值134.42亿	流通市值134.42亿	总股本8.38亿
成交额3,689万	换手率0.27%	流通股本8.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01681","market":"HK","secType":"STK","nameCN":"康臣药业","latestPrice":16.04,"timestamp":1792483700001,"preClose":15.68,"halted":0,"volume":2300000,"delay":0,"changeRate":0.02295918367346935,"floatShares":838000000,"shares":838000000,"eps":1.26,"marketStatus":"未开盘","change":0.36,"latestTime":"10-20 16:08:20","open":15.73,"high":16.18,"low":15.73,"amount":36894998,"amplitude":0.028699,"askPrice":16.04,"askSize":1000,"bidPrice":16.03,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":1.593302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":0,"adr":0,"listingDate":1387382400000,"exchange":"SEHK","adjPreClose":15.68,"dividendRate":0.049851,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":1.3081608305102674,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01681/tweets","defaultTab":"tweets","newsList":[{"id":"2674886483","title":"康臣药业获FMR LLC增持2.6万股 每股作价约14.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674886483","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674886483?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:02","pubTimestamp":1791504120,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，10月2日，FMR LLC增持康臣药业（01681）2.6万股，每股作价14.6606港元，总金额约为38.12万港元。增持后最新持股数目约为7576.06万股，持股比例为9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-10-09/doc-iniuqqhi7244632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01681","EWH","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673107995","title":"FMR LLC增持康臣药业(01681.HK)2.6万股 每股作价约14.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673107995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673107995?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:57","pubTimestamp":1791457037,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01681","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128444920","title":"康臣药业：FMR LLC增持，好仓比例升至9.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128444920","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128444920?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:23","pubTimestamp":1791451436,"startTime":"0","endTime":"0","summary":"FMR LLC于2026年10月2日在联交所场内以每股均价14.6606港元买入康臣药业股份2.60万股，涉资约38.12万港元，属场内主动交易，即在二级市场直接买卖股份。FMR LLC此次增持前持有康臣药业好仓7573.46万股，占比8.99%；增持后持股量为7576.06万股，好仓比例升至9.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131421709","title":"康臣药业：FMR LLC减持，好仓比例降至8.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131421709","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131421709?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:31","pubTimestamp":1791365496,"startTime":"0","endTime":"0","summary":"于2026年9月30日，FMR LLC在联交所场内以每股均价14.5448港元卖出康臣药业（01681）8.30万股，涉资约120.72万港元，属场内主动交易，即在二级市场直接买卖股份。FMR LLC此次减持前持有康臣药业好仓7581.76万股，占比9.01%；减持后持股量为7573.46万股，好仓比例降至8.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120638700","title":"康臣药业更新9月股份变动月报表，股本合计小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1120638700","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120638700?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:36","pubTimestamp":1791189361,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司于2026年10月5日披露截至2026年9月30日止当月的股份变动月报表。报告显示，截至该月末，公司法定股本维持5,000,000,000股，面值每股0.1港元，注册股本总额为5亿港元，未发生变动。在已发行股份方面，月初公司已发行股份为839,049,111股，库存股份为2,498,000股，合计841,547,111股。截至9月30日，公司已发行股份变更为837,937,794股，库存股份增至3,753,000股，总股份数增至841,690,794股，较上月底小幅增加143,683股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671219544","title":"FMR LLC增持康臣药业(01681)11.6万股 每股作价约14.42港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671219544","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671219544?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:32","pubTimestamp":1790681567,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月24日，FMR LLC增持康臣药业(01681)11.6万股，每股作价14.4242港元，总金额约为167.32万港元。增持后最新持股数目约为7577.46万股，持股比例为9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","BK1606","BK1191","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111501985","title":"康臣药业：FMR LLC增持，好仓比例升至9.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111501985","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111501985?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:22","pubTimestamp":1790673736,"startTime":"0","endTime":"0","summary":"FMR LLC于2026年9月24日在联交所场内以每股均价14.4242港元买入康臣药业股份11.60万股，涉资约167.32万港元，属场内主动交易，即在二级市场直接买卖股份。FMR LLC此次增持前持有康臣药业好仓7565.86万股，占比8.99%；增持后持股量为7577.46万股，好仓比例升至9.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671296161","title":"光大证券：维持康臣药业(01681)“买入”评级 肾科业务强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2671296161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671296161?lang=zh_cn&edition=full","pubTime":"2026-09-29 14:28","pubTimestamp":1790663286,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，光大证券发布研报称，康臣药业是肾科中成药龙头，稳健增长多元并进，具备高股息低估值属性，该行维持公司26-28年归母净利润预测为12.5/14.1/16.1亿元，同比增长15.5%/13.4%/13.8%，当前股价对应PE为8.3/7.3/6.5倍。维持\"买入\"评级。光大证券主要观点如下：事件：公司发布2026年中报26H1实现营业收入、归母净利润分别为17.85/5.95亿元，同比+13.8%/+19.5%。26H1收入稳健增长，盈利能力增强26H1公司利润端增速高于收入端，主要得益于管理效益的提升和营业总成本有效控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601788","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670443768","title":"【券商聚焦】平安证券维持康臣药业（01681）推荐评级 指上半年业绩增长亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2670443768","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670443768?lang=zh_cn&edition=full","pubTime":"2026-09-25 14:48","pubTimestamp":1790318899,"startTime":"0","endTime":"0","summary":"金吾财讯 | 平安证券发布研报指，康臣药业 2026年上半年业绩增长较为亮眼，持续丰厚股东回报，维持“推荐”评级。公司2026年中期现金分红总额2.77亿元，每股派息0.33元。研报指，收入增长主要系公司在全国销售网络拓展，以及提升产品市场覆盖率。盈利预测方面，平安证券维持此前预测，预计公司2026-2028年营业收入分别为37.66亿元、41.10亿元、44.88亿元，分别同比增长10.2%、9.1%、9.2%；归母净利润分别为12.66亿元、14.32亿元、15.82亿元，分别同比增长17.4%、13.1%、10.5%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992507","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01681","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104416879","title":"康臣药业2026年中期营收17.85亿元，经调整净利润5.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104416879","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104416879?lang=zh_cn&edition=full","pubTime":"2026-09-24 06:22","pubTimestamp":1790202154,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司公布截至2026年6月30日止六个月财务数据，报告期内营收17.85亿元，同比增长13.8%。同期，经调整净利润录得5.95亿元，同比增长19.5%。期内毛利率为81.4%，较上年同期提升4.3个百分点；经营活动产生的现金流净额为7.81亿元，同比增长58.6%。销售及管理费用中，销售及分销成本同比增长7.8%；行政开支同比增长35.7%。研发投入为0.91亿元，对比上年同期提升近一倍，主要反映组织架构优化及相关投入增加。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康臣药业2026年中期营收17.85亿元，经调整净利润5.95亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191830552","title":"康臣药业回购5万股股份，耗资约65.53万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191830552","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191830552?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:27","pubTimestamp":1789640869,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司于2026年9月17日公告回购公司股份，共计回购股份50,000股，占当日现有已发行股本约0.006%。此次回购的每股价格介乎每股13.09港元至13.15港元，总成交额约65.53万港元。回购股份将列作公司库藏股。回购完成后，公司已发行股本总数增至841,589,615股，其中837,836,615股为已发行股份，库藏股股份数增至3,753,000股。公司强调已严格遵守香港联合交易所有限公司证券上市规则及其他相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业回购5万股股份，耗资约65.53万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124141911","title":"康臣药业回购19.3万股股份，耗资约252.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124141911","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124141911?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:25","pubTimestamp":1789561547,"startTime":"0","endTime":"0","summary":"2026年9月16日，康臣药业发布翌日披露报表称，公司于当日在香港联交所场内回购193,000股普通股，约占回购前已发行股本的0.023%。每股回购价格介乎13.05港元至13.20港元不等，合计耗资约2,528,190港元。本次回购股份将作为公司库存股份持有。公告显示，本次回购完成后，公司已发行股份总数维持841,589,615股，其中837,886,615股为流通股，3,703,000股为库存股份。公司在公告中确认，本次回购已严格遵守香港联交所证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业回购19.3万股股份，耗资约252.82万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667398361","title":"康臣药业(01681)9月16日斥资252.8万港元回购19.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667398361","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667398361?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:22","pubTimestamp":1789561361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)发布公告，于2026年9月16日斥资252.8万港元回购19.3万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","BK1191","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186543405","title":"康臣药业9月15日回购30.10万股股份，涉资约398.63万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186543405","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186543405?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:52","pubTimestamp":1789465949,"startTime":"0","endTime":"0","summary":"康臣药业于2026年9月15日发布公告称，公司当天在香港联交所场内回购普通股30.10万股，约占该次回购前公司已发行股本的0.0359%。回购价格区间介乎每股13.16港元至13.29港元，合计付出约398.63万港元。回购后，公司已发行股份总数为838,079,615股，库存股数为3,510,000股，合计841,589,615股。截至目前，康臣药业已根据该回购授权在市场合计回购3,166,000股，占通过回购授权时已发行股本约3.7637%。上述操作均已遵守香港联交所主板上市规则及相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业9月15日回购30.10万股股份，涉资约398.63万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667645591","title":"康臣药业(01681)9月15日斥资398.63万港元回购30.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645591","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667645591?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:51","pubTimestamp":1789465887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)发布公告，于2026年9月15日，该公司斥资398.63万港元回购30.1万股股份，每股回购价13.16-13.29港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01681","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176598515","title":"康臣药业9月11日回购40.6万股股份，合计支出约527万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176598515","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176598515?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:20","pubTimestamp":1789122050,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司于2026年9月11日公告，公司于香港联交所场内回购普通股合计406,000股，占回购前已发行股本约0.0484%。此次回购每股价格介乎每股12.89港元至13.06港元，耗资共计约5,269,980港元。本次股份变动完成后，公司已发行股本减少至838,338,111股，库存股增加至3,209,000股，公司股本总数维持在841,547,111股。公司表示，本次回购系依据2026年5月26日通过的回购授权执行，该授权允许公司回购最多84,120,311股股份。公告由公司秘书高海恩签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业9月11日回购40.6万股股份，合计支出约527万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143548442","title":"康臣药业9月10日回购30.5万股，涉资约399.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143548442","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143548442?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:52","pubTimestamp":1789037551,"startTime":"0","endTime":"0","summary":"康臣药业于2026年9月10日发布公告，披露当日于香港联交所场内回购30.5万股普通股，约占该公司既有已发行股本总数的0.0364%。回购价格区间为每股12.87港元至13.16港元，合计耗资约399.94万港元。此次回购完成后，公司已发行股本变动至838,744,111股，库藏股数增至2,803,000股。根据公告，康臣药业于2026年5月26日获得回购授权，可购回最多84,120,311股。康臣药业确认，本次回购已获得公司董事会正式授权，并遵守香港联交所上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业9月10日回购30.5万股，涉资约399.94万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666756741","title":"康臣药业(01681)9月10日耗资399.935万港元回购30.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666756741","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666756741?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:51","pubTimestamp":1789037499,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)公布，2026年9月10日耗资399.935万港元回购30.5万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118321439","title":"康臣药业2026年8月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1118321439","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118321439?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:36","pubTimestamp":1788262590,"startTime":"0","endTime":"0","summary":"2026年9月1日，康臣药业集团有限公司公布截至2026年8月31日的股份变动月报。报告期内，公司法定注册股本维持5,000,000,000股，对应股本总额约5亿港元，无新增或减少。在股权激励方面，2013年12月2日采纳的购股权计划上月底结存7,074,153份股份期权，于本月内全部变动，8月底余额为0；2024年5月31日采纳的购股权计划尚未有变动，目前可发行或转让的潜在股份总数为84,281,191股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729891","title":"港股公告掘金 | 利润同比增加98.28%接近翻倍，不同集团发布上半年业绩公告，计划加大核心产品的AI升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729891","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729891?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:07","pubTimestamp":1787792839,"startTime":"0","endTime":"0","summary":"重大事项：百度集团-SW(09888)：于香港联交所自愿转换为双重主要上市中国宝力科技(00164)于蒙古部署其干磨干选业务方面取得重大进展博安生物(06955)：BA2201(TL1A/IL-23)临床试验申请获CDE受理康希诺生物(06185)附属与德普世生物订立mRNA个性化治疗型肿瘤疫苗共同开发战略合作框架协议石药集团(01093)：SYS6010用于EGFR TKI治疗失败的EGFR突变","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0229945570.USD","CHAT","LU0630378429.USD","BK1258","LU0531971595.HKD","LU0821914370.USD","HK0000320264.USD","LU0244354667.USD","LU0417516902.SGD","LU0456827905.SGD","09888","BK1193","LU0856984785.SGD","HK0000306685.HKD","LU0052750758.USD","LU0307460666.USD","00164","LU0287142896.SGD","LU0043850808.USD","AGIX","IE00B3M56506.USD","LU0315179316.USD","LU0359202008.SGD","LU0823426480.USD","LU1115378108.SGD","VXUS","BK1191","LU2476274308.USD","LU0708995583.HKD","06090","00836","BIDU","KCAI","LU0359201612.USD","QTOC","LU0164865239.USD","BK1207","BK1575","SG9999002463.SGD","BK4585","89888","AIPO","TCHI","LU0543330566.HKD","LU1188198961.HKD","ARTY","LU0163747925.USD","LU0197773673.USD","01681","VTHR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinaconsun.com","stockEarnings":[{"period":"1week","weight":0.056},{"period":"1month","weight":0.2051},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.0837},{"period":"1year","weight":0.0999},{"period":"ytd","weight":0.0851}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康臣药业集团有限公司是一家主要从事药品生产及销售业务的公司。该公司通过两个部门开展业务。康臣药业分部主要从事生产及销售现代中成药及医用成像对比剂业务。玉林制药分部主要从事生产及销售传统中成药业务。该公司的产品主要包括肾科药物、妇儿药物、对比剂、骨科药物、皮肤科药物、肝胆药物和其他。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.045405},{"month":2,"riseRate":0.538462,"avgChangeRate":0.016854},{"month":3,"riseRate":0.461538,"avgChangeRate":0.017226},{"month":4,"riseRate":0.692308,"avgChangeRate":0.059355},{"month":5,"riseRate":0.538462,"avgChangeRate":0.023091},{"month":6,"riseRate":0.384615,"avgChangeRate":-0.004071},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.002843},{"month":8,"riseRate":0.538462,"avgChangeRate":0.010796},{"month":9,"riseRate":0.615385,"avgChangeRate":0.035981},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.017685},{"month":11,"riseRate":0.5,"avgChangeRate":0.008662},{"month":12,"riseRate":0.583333,"avgChangeRate":0.021459}],"exchange":"SEHK","name":"康臣药业","nameEN":"CONSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康臣药业,01681,康臣药业股票,康臣药业股票老虎,康臣药业股票老虎国际,康臣药业行情,康臣药业股票行情,康臣药业股价,康臣药业股市,康臣药业股票价格,康臣药业股票交易,康臣药业股票购买,康臣药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}